A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis

This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an inadequate response to a traditional, nonbiologic disease-modifying antirheumatic drug. Adalimumab is used as a comparator.

本研究为一项为期12个月的临床试验，旨在评估托法替尼（tofactinib）对传统非生物类改善病情抗风湿药（disease-modifying antirheumatic drug）应答不佳的活动性银屑病关节炎（active psoriatic arthritis）患者的有效性与安全性，具体包括改善该疾病的体征与症状、提升患者躯体功能以及维持骨骼结构，试验以阿达木单抗（Adalimumab）作为对照药物。